您当前所在的位置:首页 > 产品中心 > 产品信息
VU0255035 hydrate_分子结构_CAS_1135243-19-4(anhydrous))
点击图片或这里关闭

VU0255035 hydrate

产品号 V3765 公司名称 Sigma Aldrich
CAS号 1135243-19-4(anhydrous) 公司网站 http://www.sigmaaldrich.com
分子式 C18H22N6O4S2 电 话 1-800-521-8956
分子量 450.53508 传 真
纯 度 ≥98% (HPLC) 电子邮件
保 存 Chembase数据库ID: 154562

产品价格信息

请登录

产品别名

标题
VU0255035 hydrate
IUPAC标准名
S-(2,1,3-benzothiadiazol-4-yl)-3-oxo-3-[4-(pyridin-4-yl)piperazin-1-yl]propane-1-sulfonamido hydrate
IUPAC传统名
S-(2,1,3-benzothiadiazol-4-yl)-3-oxo-3-[4-(pyridin-4-yl)piperazin-1-yl]propane-1-sulfonamido hydrate
别名
ML012
N-[3-oxo-3-[4-(4-pyridinyl)-1-piperazinyl]propyl]-2,1,3-benzothiadiazole-4-sulfonamide hydrate
CID24768606
N-(3-oxo-3-(4-(pyridine-4-yl)piperazin-1-yl)propyl)benzo[c][1,2,5]thiadiazole-4-sulfonamide hydrate

产品登记号

MDL号 MFCD16875440
CAS号 1135243-19-4(anhydrous)

产品性质

Empirical Formula (Hill Notation) C18H20N6O3S2 · xH2O
纯度 ≥98% (HPLC)
外观 yellow powder
溶解度 DMSO: >5 mg/mL
GHS危险品标识 GHS07
GHS警示词 Warning
GHS危险声明 H302-H315-H319-H335
欧盟危险性物质标志 有害性(Harmful) 有害性(Harmful) (Xn)
MSDS下载 下载链接
GHS警示性声明 P261-P305 + P351 + P338
危险公开号 22-36/37/38
安全公开号 26
保存温度 -20°C
德国WGK号 3

产品详细信息

详细说明 (English)
Biochem/physiol Actions
VU0255035 is the first highly selective antagonist at the orthosteric site of the M1 receptor (75-fold selective for M1 relative to other muscarininc subtypes and devoid of activity at other GPCRs, ion channels, transporters and kinases). There are no highly selective M1 muscarinic receptor antagonists. The existing non-selective drugs do not permit direct evaluation of the role of M1 receptors in CNS fucntions and do not premit therapeutic targeting of M1 receptors in various disease states in which M1 receptors are implicated (epilepsy, Parkinson′s disease, attention and cognitive disorders, dystonia, etc).
详细说明 (简体中文)
Biochem/physiol Actions
VU0255035 is the first highly selective antagonist at the orthosteric site of the M1 receptor (75-fold selective for M1 relative to other muscarininc subtypes and devoid of activity at other GPCRs, ion channels, transporters and kinases). There are no highly selective M1 muscarinic receptor antagonists. The existing non-selective drugs do not permit direct evaluation of the role of M1 receptors in CNS fucntions and do not premit therapeutic targeting of M1 receptors in various disease states in which M1 receptors are implicated (epilepsy, Parkinson′s disease, attention and cognitive disorders, dystonia, etc).

参考文献